| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04493216 Details | 2023-11-18 Interventional | 2 | 169 | Dolutegravir HIV Infections | Company decision to stop compound development. The decision is not based on any safety or
efficacy concerns. It reflects the company strategy for portfolio progression. - | |||
| NCT04409873 Details | 2023-11-18 Interventional | 2 | 54 | Cetylpyridinium Chlorine dioxid… Hydrogen Peroxi… Listerine COVID-19 Coronavirus Inf… Pharyngeal Dise… Severe Acute Re… Virus Diseases SARS-CoV 2 Severe Acute Re… Virus Disease | The funder decided not to continue funding, causing enrollment to cease prematurely and
curtailing originally planned analyses. Participants with any samples collected after the
baseline pre-rinse samples were included in the analysis. Study support was withdrawn by Funder, so enrollment ended, and only a priori planned interim analyses were performed. | |||
| NCT04329949 Details | 2023-11-18 Interventional | 3 | 43 | Paclitaxel Adenocarcinoma Metastatic Panc… | The independent data monitoring committee found no safety issues, however the observed response
rate did not meet the predefined threshold for continuing the study. The study was terminated
by the Sponsor. The independent data monitoring committee found no safety issues, however the observed response rate did not meet the predefined threshold for continuing the study. The study was terminated by the Sponsor. | |||
| NCT03624036 2018-001923-38 Details | 2023-11-18 Interventional | 1 | [1 Refs] | 16 | Brexucabtagene … Cyclophosphamid… Fludarabine Leukemia Leukemia, Lymph… Leukemia, Lymph… Lymphoma Relapsed/Refrac… | Development program terminated - | ||
| NCT02907983 Details | 2023-11-18 Interventional | 2 | - | Bupivacaine Hot Flashes Hot Flushes Vasomotor Sympt… | IRB Audit Review - | |||
| NCT02813655 2015-003357-17 Details | 2023-11-18 Interventional | 2 | 46 | Cosyntropin Headache Post-Dural Punc… Wounds and Inju… Post-dural Punc… | Interim analysis and decision of the independent committee, investigators and sponsor
(futility) (2023/10/05) - | |||
| NCT02743806 2016-000678-40 Details | 2023-11-18 Interventional | 4 | 331 | Vedolizumab Colitis Colitis, Ulcera… Crohn Disease Ulcer | Early Completed - Alternative Source of Drug Available - | |||
| NCT02530502 Details | 2023-11-18 Interventional | 1 | 4 | Pembrolizumab Temozolomide Glioblastoma Adult Glioblast… | The protocol was amendment to be stopped after phase I (phase 2 removed from protocol) - | |||
| NCT02432417 Details | 2023-11-18 Interventional | 2 | 0 | Chloroquine Astrocytoma Glioblastoma Astrocytoma, Gr… | The study was withdrawn due to a lack of funding. The researchers were unable to secure the
necessary financial support to continue and complete the trial. - | |||
| NCT06006286 Details | 2023-11-15 Interventional | 1/2 | 0 | Atezolizumab Bevacizumab Carcinoma Carcinoma, Hepa… Metastatic Hepa… | 0 participants registered - | |||
| NCT05458102 Details | 2023-11-15 Interventional | 1 | 18 | Cobicistat Rifabutin Vesatolimod Voriconazole Acquired Immuno… HIV Infections Human Immunodef… | Sponsor's decision to change the clinical development plan of this molecule. This decision is
not based on efficacy or safety concerns. - | |||
| NCT04068610 2019-000974-44 Details | 2023-11-15 Interventional | 1/2 | 61 | Bevacizumab Durvalumab Colorectal Neop… Metastatic Micr… | On 17 February 2022, the decision was made to terminate the clinical study because superior
efficacy was not observed for the novel study drug combinations under investigation. On 17 February 2022, the decision was made to terminate the clinical study because superior efficacy was not observed for the novel study drug combinations under investigation. | |||
| NCT03860844 2018-002697-45 2018-002697-45 Details | 2023-11-15 Interventional | 2 | 67 | Asparaginase Cyclophosphamid… Cytarabine Daunorubicin Dexamethasone Doxorubicin Etoposide Fludarabine Hydroxyurea Idarubicin Methotrexate Mitoxantrone Pegaspargase Vincristine Leukemia Leukemia, Lymph… Leukemia, Myelo… Leukemia, Myelo… Precursor Cell … Acute Lymphobla… Acute Myeloid L… | Study was prematurely stopped due to sponsor decision (stage 2 efficacy criteria not met); not
due to safety concerns. The study was prematurely stopped due to sponsor decision (stage 2 efficacy criteria not met) and not due to safety concerns. | |||
| NCT02826161 Details | 2023-11-15 Interventional | 3 | 4 | Paclitaxel Carcinoma, Non-… | Change of treatment landscape and evolving standard of care On 12 June 2017 the sponsor notified study investigator that the study was terminated because of the rapidly evolving standard of care for patients with NSCLC. At the time of the termination, there were only 4 patients randomized (3 to the control arm and 1 to the napabucasin arm). Due to the small sample size, neither safety or efficacy data were analyzed or summarized for this study. | |||
| NCT02357849 Details | 2023-11-15 Interventional | 4 | 9 | Aripiprazole Fluoxetine Mental Disorder… Psychotic Disor… Attenuated Psyc… | - - | |||
| NCT01531803 Details | 2023-11-15 Interventional | 4 | 3 | Pharmaceutical … Hypovolemia | Per FDA CBER letter dated July 15, 2015, Kedrion SpA was released from the PMC to perform the
study with Kedbumin 25% in pediatric patients. - | |||
| NCT00742807 Details | 2023-11-15 Interventional | 4 | 0 | Alfentanil Pain | No investigator to follow-up - | |||
| NCT05427981 Details | 2023-11-14 Interventional | 3 | 0 | Buprenorphine Depressive Diso… Depressive Diso… Suicidal Ideati… Major Depressiv… | U.S. Department of Health and Human Services OHRP issued an FWA restriction on NYSPI research
that included a pause of human subjects research as of June 23, 2023. This study will not
resume recruitment after the resumption of research. - | |||
| NCT04820686 Details | 2023-11-14 Interventional | 2 | 65 | Entecavir Tenofovir Hepatitis Hepatitis A Hepatitis B Hepatitis B, Ch… Hepatitis, Chro… Chronic Hepatit… | Sponsor decision Study ABI-H0731-204 was terminated early by the study Sponsor for strategic reasons to prioritize research and development efforts on finite and curative HBV therapies. As a result, not all subjects completed Week 96 and some outcome measures were impacted. | |||
| NCT04066491 2019-001992-35 Details | 2023-11-14 Interventional | 2/3 | [1 Refs] | 309 | Gemcitabine Biliary Tract N… Cholangiocarcin… Gallbladder Neo… Biliary Tract C… Gallbladder Can… | Based on a review of data conducted by the Independent Data Monitoring Committee (IDMC),
Sponsor decided to discontinue this study as the study was unlikely to achieve the primary
objective of overall survival. Data collection and analysis of Pharmacokinetics and Immunogenicity were omitted and not conducted due to business reason. |